Minimally invasive adenocarcinomas of the lung

Advances in Anatomic Pathology

Volumn 16, Issue 3, 2009, Pages 166-171

  Dacic, Sanja ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Histology; Lung; Minimally invasive; Prognosis

Indexed keywords

CANCER CLASSIFICATION; CANCER INVASION; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL FEATURE; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MIXED TUMOR; MOLECULAR DYNAMICS; NOMENCLATURE; PATHOLOGIST; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; WORLD HEALTH ORGANIZATION; ADENOCARCINOMA; GENETICS; LUNG TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; HUMANS; LUNG NEOPLASMS; MIXED TUMOR, MALIGNANT; NEOPLASM INVASIVENESS;

EID: 66349106895     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181a19e3b     Document Type: Review

References (32)

1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004:35-44.
2. Yousem SA, Beasley MB. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch Pathol Lab Med. 2007;131:1027-1032.
3. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005;23:3279-3287. (Pubitemid 46211352)
4. Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncology; Official Publication of the International Association for the Study of Lung Cancer. 2006;1:S13-S19.
5. Kodama K, Higashiyama M, Yokouchi H, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer. 2001;33:17-25. (Pubitemid 32586777)
6. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
7. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000;69:893-897. (Pubitemid 30184718)
8. Maeshima AM, Niki T, Maeshima A, et al. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer. 2002;95:2546-2554. (Pubitemid 35424041)
9. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937-951. (Pubitemid 36758897)
10. Sakurai H, Maeshima A, Watanabe SI, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28:198-206. (Pubitemid 38124728)
11. Shimosato Y, Suzuki A, Hashimoto T, et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol. 1980;4:365-373. (Pubitemid 10035269)
12. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29:179-188.
13. Rena O, Papalia E, Ruffini E, et al. Stage I pure bronchioloalveolar carcinoma: recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardiothorac Surg. 2003;23:409-414. (Pubitemid 36298552)
14. Yim J, Zhu L-C, Chiriboga L, et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007;20:233-241. (Pubitemid 46422178)
15. Noguchi M, Minami Y, Iijima T, et al. Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int. 2005;55:8-13. (Pubitemid 40289251)
16. Koga T, Hashimoto S, Sugio K, et al. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res. 2001;7:1730-1738. (Pubitemid 32708642)
17. Aoyagi Y, Yokose T, Minami Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res. 2001;61:7950-7954. (Pubitemid 33049386)
18. Borczuk AC, Kim HK, Yegen HA, et al. Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med. 2005;172:729-737.
19. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
20. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
21. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311. (Pubitemid 39209661)
22. Blons H, Cote J-F, Le Corre D, et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol. 2006;30:1309-1315. (Pubitemid 44454711)
23. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472-1478.
24. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810-827.
25. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29:633-639. (Pubitemid 40577873)
26. Arenberg D. American College of Chest Physicians. Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:306S-313S.
27. Rusch VW, Tsuchiya R, Tsuboi M, et al. Surgery for bronchioloalveolar carcinoma and "very early" adenocarcinoma: an evolving standard of care? J Thorac Oncol. 2006;1:S27-S31.
28. Inoue M, Takakuwa T, Minami M, et al. Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2008;135:830-836.
29. Nakayama H, Yamada K, Saito H, et al. Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging. Ann Thorac Surg. 2007;84:1675-1679. (Pubitemid 47588103)
30. Asamura H, Suzuki K, Watanabe SI, et al. A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. Ann Thorac Surg. 2003;76:1016-1022. (Pubitemid 37204698)
31. Nakamura H, Saji H, Ogata A, et al. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection. Lung Cancer. 2004;44:61-68. (Pubitemid 38317262)
32. Asamura H. Minimally invasive approach to early, peripheral adenocarcinoma with ground-glass opacity appearance. Ann Thorac Surg. 2008;85:S701-S704.